StocksMedium•30 September 2026•
1 min read
FDA Expands Approval for Bristol Myers Squibb's CAMZYOS to Pediatric Patients
Key Facts
1The U.S. FDA approved an expanded indication for CAMZYOS (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients.
The U.S. FDA approved an expanded indication for CAMZYOS (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients. Business Wire reported that the approval follows clinical data supporting the efficacy and safety of the treatment across different age groups.
The regulatory decision broadens the clinical application for Bristol Myers Squibb's therapy in managing heart muscle conditions. Regulatory approvals for expanded indications typically increase the addressable market within the biotechnology and healthcare sectors.